{
  "run_date": "2026-02-08T17:29:09.703356+00:00",
  "stocks_scanned": 235,
  "top_picks": [
    {
      "ticker": "TKA",
      "name": "thyssenkrupp AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 11.655,
      "currency": "EUR",
      "market_cap": 9659455488,
      "pe_ratio": 15.54,
      "forward_pe": 10.92704,
      "roe": 5.0869998,
      "dividend_yield": 129.0,
      "momentum_6m": 19.602403566203286,
      "momentum_12m": 157.50894348275168,
      "rsi_14": 66.40772694967322,
      "alpha_score": 82,
      "score_breakdown": {
        "value": 21,
        "quality": 15,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 8
      },
      "yahoo_url": "https://finance.yahoo.com/quote/TKA.DE",
      "stop_loss": 10.48,
      "take_profit": 13.41,
      "signal": "HOLD",
      "confidence": "MEDIUM",
      "reasoning": "thyssenkrupp's FY2025 turnaround to profitability and robust order intake growth (up 15% for the year, driven by Marine Systems) provide a positive base, aligning with strong recent stock momentum and an attractive P/E of 15.5.[1] However, FY2026 forecasts a net loss and sales decline amid persistent weak demand and restructuring costs at Steel Europe, tempering near-term upside in a challenging European industrials context.[1][3] Earnings growth trajectory (26% average annual rate) offers long-term potential, but volatility warrants caution.[6]",
      "company_overview": "thyssenkrupp AG is a German industrial conglomerate operating in sectors including steel, materials services, automotive technology, marine systems, and decarbonization technologies, with a focus on ongoing transformation amid challenging market conditions.[1][3] In fiscal 2025 (ended September 30, 2025), the company achieved net income of 532 million euros (vs. prior-year loss) and adjusted EBIT of 640 million euros, though sales fell 6% to 32.8 billion euros due to demand fluctuations.[1] The stock has shown strong momentum with a 157.5% 12-month return, supported by Q4 profitability, but FY2026 guidance signals headwinds including projected net losses.[1]",
      "key_developments": [
        "Reported Q4 FY2025 profit of 639 million euros (vs. prior-year loss of 1.06 billion euros), with adjusted EBIT up 82% to 274 million euros, though sales dropped 6% and orders 12%.[1]",
        "FY2025 full-year net income of 532 million euros and adjusted EBIT of 640 million euros; proposes 0.15 euro per share dividend for approval at January 30, 2026 AGM (already held).[1][3]",
        "Issued FY2026 guidance expecting net loss of 400-800 million euros (due to Steel Europe restructuring provisions) and sales flat to -2%, with mixed segment growth.[1]"
      ],
      "catalysts": [
        "Q1 FY2026 interim report and conference call on February 12, 2026, with CEO and CFO commentary, potentially updating guidance or restructuring progress.[2][3][4]",
        "Dividend approval confirmation post-AGM (held January 30, 2026), providing minor yield support.[1][3]"
      ],
      "risk_factors": [
        "Projected FY2026 net loss of 400-800 million euros from Steel Europe restructuring and weak sales/orders in segments like Automotive Technology.[1]",
        "Broader challenging macroeconomic environment, including demand fluctuations and price pressures in European steel/industrials markets.[1][3]"
      ],
      "sources": [
        "https://www.nasdaq.com/articles/thyssenkrupp-turns-profit-q4-sales-orders-down-sees-loss-weak-sales-fy26",
        "https://www.thyssenkrupp.com/en/investors/calendar",
        "https://www.thyssenkrupp.com/en/investors",
        "https://www.thyssenkrupp.com/en/investors/reporting-and-publications",
        "https://www.marketscreener.com/quote/stock/THYSSENKRUPP-AG-436698/finances/",
        "https://simplywall.st/stocks/de/materials/etr-tka/thyssenkrupp-shares/past",
        "https://eulerpool.com/en/stock/thyssenkrupp-Stock-DE0007500001/NetIncome"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 5.6
    },
    {
      "ticker": "EN",
      "name": "Bouygues SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 48.25,
      "currency": "EUR",
      "market_cap": 18544437248,
      "pe_ratio": 17.545454,
      "forward_pe": 13.719469,
      "roe": 8.397,
      "dividend_yield": 415.00000000000006,
      "momentum_6m": 25.84767816372373,
      "momentum_12m": 60.73101046194995,
      "rsi_14": 69.28839450740628,
      "alpha_score": 78,
      "score_breakdown": {
        "value": 21,
        "quality": 9,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/EN.PA",
      "stop_loss": 46.4,
      "take_profit": 51.03,
      "signal": "HOLD",
      "confidence": "LOW",
      "reasoning": "Limited recent news provides no strong directional signals, with the stock in a weak rising short-term trend but rated as a \"hold/accumulate\" due to insufficient buy catalysts.[1] Strong historical returns (+60.7% over 12m) and an Alpha Score of 78/100 suggest momentum, but low volume and lack of fresh developments temper upside in the current European industrials context.[1][user query] Outlook for next 3-6 months points to modest 5.92% rise potential (90% probability to $9.20-$9.86 on OTC), but data gaps limit conviction.[1]",
      "company_overview": "Bouygues SA is a diversified French services group operating in over 80 countries with approximately 200,000 employees, focusing on **construction** (Colas, Bouygues Construction, Bouygues Immobilier), **energies & services** (Equans), **telecoms** (Bouygues Telecom), and **media** (TF1).[2][3] The company maintains a stable share structure, with 385,439,418 shares and around 496-497 million voting rights as of January 31, 2026.[2][3] Its EPA-listed stock (EN) trades at 48.25 EUR, reflecting strong recent performance with +25.8% over 6 months and +60.7% over 12 months, supported by a P/E of 17.5 and ROE of 8.4%.[user query]",
      "key_developments": [
        "Monthly disclosure on February 2, 2026, confirming total shares at 385,439,418 and voting rights at 497,648,749 (theoretical) / 496,550,003 (exercisable) as of January 31, 2026, indicating no material changes in capital structure.[2][3]",
        "Stock price rose 0.364% on February 3, 2026 (last trading day referenced), from $10.98 to $11.02 (OTC: BOUYY equivalent), within a weak short-term rising trend.[1]",
        "No other major news or events reported in the last 30 days; trading volume remains low, with recent sessions showing controlled movements and positive moving average signals.[1]"
      ],
      "catalysts": [
        "Upcoming earnings or sector-specific announcements in construction/telecoms, potentially driving momentum given high Alpha catalyst score (13/25).[user query]",
        "Potential volume pickup or breakout above short-term resistance (~$9.11-$9.18 OTC), signaling trend continuation.[1]"
      ],
      "risk_factors": [
        "Low/falling trading volume creating divergence signals, increasing short-term reversal risk despite rising prices.[1]",
        "Breakdown below key supports ($8.91-$9.00 OTC), potentially triggering sell signals from MACD and moving averages.[1]"
      ],
      "sources": [
        "https://stockinvest.us/stock/BOUYY",
        "https://live.euronext.com/en/products/equities/company-news/2026-02-02-bouygues-monthly-disclosure-total-number-shares-and",
        "https://www.globenewswire.com/news-release/2026/02/02/3230458/0/en/bouygues-monthly-disclosure-of-the-total-number-of-shares-and-voting-rights.html",
        "https://ng.investing.com/equities/bouygues-n-historical-data"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 3.7
    },
    {
      "ticker": "AZN",
      "name": "AstraZeneca PLC",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 14104.0,
      "currency": "GBP",
      "market_cap": 218651983872,
      "pe_ratio": 31.623316,
      "forward_pe": 18.686577,
      "roe": 21.674,
      "dividend_yield": 173.0,
      "momentum_6m": 27.799927509967382,
      "momentum_12m": 20.387470630408732,
      "rsi_14": 54.043839758125465,
      "alpha_score": 75,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AZN.L",
      "stop_loss": 13430.71,
      "take_profit": 15113.93,
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "AstraZeneca's NYSE listing enhances liquidity and US investor access, supporting its high momentum (Alpha Score 25/25) and quality profile amid a strong 27.8% 6-month return.[1] Pipeline progress toward $80 billion 2030 revenue provides a clear growth trajectory in a favorable healthcare sector, though elevated P/E of 31.6 warrants monitoring for valuation risks.[1] Global harmonization positions AZN well in both European and US markets.",
      "company_overview": "AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on oncology, rare diseases, and bioPharmaceuticals, maintaining a strong market position with listings on the London Stock Exchange (LSE), Nasdaq Stockholm, and now the New York Stock Exchange (NYSE).[1] The company has delivered robust recent performance, with a 6-month return of +27.8% and 12-month return of +20.4%, supported by a high-quality pipeline and reiterated 2030 ambitions for $80 billion in annual revenue and 20 new medicine launches.[1] Its current metrics include a P/E ratio of 31.6, ROE of 21.7%, and an Alpha Score of 75/100, reflecting solid momentum and quality despite modest value scores.",
      "key_developments": [
        "AstraZeneca commenced trading of its ordinary shares on the NYSE under the AZN ticker, creating a harmonized global listing structure alongside LSE and Nasdaq Stockholm, effective recently to access the world's largest capital market and broaden its investor base.[1]",
        "The NYSE listing replaces the prior American Depositary Share (ADS) trading and transitions US dollar bonds to NYSE, with no changes to UK/Swedish listings or index memberships.[1]",
        "Management highlighted strong pipeline momentum, with readouts representing over $10 billion in peak revenue potential, reinforcing confidence in long-term growth targets.[1]"
      ],
      "catalysts": [
        "Pipeline readouts with >$10 billion peak revenue potential, expected to drive near-term visibility into 2030 ambitions.[1]",
        "Potential index inclusions or increased institutional buying following NYSE listing and enhanced US liquidity.[1]"
      ],
      "risk_factors": [
        "High P/E ratio (31.6) exposes the stock to valuation compression if growth expectations falter.[1]",
        "Broader healthcare sector risks, including regulatory hurdles or pipeline setbacks not detailed in recent updates.[1]"
      ],
      "sources": [
        "https://www.stocktitan.net/sec-filings/AZN/6-k-astrazeneca-plc-current-report-foreign-issuer-5cf8521c5fa8.html"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 13.4
    },
    {
      "ticker": "DG",
      "name": "Vinci SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 134.2,
      "currency": "EUR",
      "market_cap": 74474168320,
      "pe_ratio": 15.496535,
      "forward_pe": 13.201904,
      "roe": 15.433,
      "dividend_yield": 373.0,
      "momentum_6m": 8.321016006141392,
      "momentum_12m": 30.518547803182727,
      "rsi_14": 84.94207993778656,
      "alpha_score": 72,
      "score_breakdown": {
        "value": 21,
        "quality": 16,
        "momentum": 20,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/DG.PA",
      "stop_loss": 128.55,
      "take_profit": 142.67,
      "signal": "BUY",
      "confidence": "MEDIUM",
      "reasoning": "Vinci's strong 2025 financials, including record cash flow and dividend hike, support ongoing growth amid resilient infrastructure demand, with management guiding for 2026 expansion despite macro headwinds.[1][2] Recent stock momentum (12m return +30.5%, Alpha Score 72/100) and low beta (0.75) indicate stability, though tempered by analyst concerns on taxes and concessions.[1][3][4] Portfolio reviews could unlock value via asset disposals.[2]",
      "company_overview": "Vinci SA is a leading European construction and infrastructure company with three main units: Concessions (motorways and airports), Energy, and Construction, holding a strong market position evidenced by its \u20ac67.63B market cap and record 2025 free cash flow of \u20ac7.01B.[1][2] In 2025, the company achieved revenue of \u20ac74.60B (up 4.2% YoY), net profit of \u20ac4.90B (up 0.8%), and proposed a dividend increase to \u20ac5/share from \u20ac4.75, driving a 9.91% stock surge to \u20ac134.20 on February 6, 2026, following full-year results.[1][2][3] Despite a turbulent global macroeconomic environment, Vinci entered 2026 with confidence, forecasting further growth in revenue, earnings, and free cash flow around \u20ac6B.[2]",
      "key_developments": [
        "Reported record 2025 free cash flow of \u20ac7.01B (up from \u20ac6.81B), revenue beating estimates at \u20ac74.60B, and net profit of \u20ac4.90B, leading to a 6.4% stock jump initially and further gains to \u20ac134.20.[2][3]",
        "Nine-month 2025 revenues rose 3.7% to \u20ac54.25B (2.0% like-for-like), with Q1 2025 revenue up 4% to \u20ac16.3B driven by 8% Concessions growth.[1]",
        "BofA downgraded to Underperform citing French tax risks, muted 3.5% annual EBIT growth forecast for 2026-27, and 40% EBITDA drop in Concessions by 2037 due to expiring concessions.[4]"
      ],
      "catalysts": [
        "Q1 2026 earnings release (expected around late April, following prior patterns), potentially confirming guided revenue/EBIT growth.[1][2]",
        "Outcomes from ongoing portfolio reviews in Concessions, Energy, and Construction units, including potential asset sales.[2]",
        "Dividend payment post-ex-date (likely spring 2026, following \u20ac5/share proposal).[1][2]"
      ],
      "risk_factors": [
        "French tax risks and expiring concessions, with BofA forecasting 40% Concessions EBITDA decline by 2037 and only 3.5% group EBIT growth.[4][7]",
        "Muted organic growth across segments amid global macroeconomic/geopolitical turbulence, as highlighted by management and analysts.[2][4]"
      ],
      "sources": [
        "https://stockanalysis.com/quote/epa/DG/",
        "https://www.marketscreener.com/news/vinci-shares-jump-after-revenue-increase-record-free-cash-flow-ce7e5ad9d88bf126",
        "https://stockinvest.us/stock/DG.PA",
        "https://www.investing.com/news/analyst-ratings/vinci-stock-downgraded-to-underperform-by-bofa-on-french-tax-risks-93CH-4443975",
        "https://www.smartkarma.com/home/newswire/earnings-alerts/vinci-sa-dg-earnings-fy-revenue-aligns-with-estimates-and-exceeds-free-cash-flow-expectations/",
        "https://www.vinci.com/en/vinci/page/cours_de_l_action",
        "https://www.morningstar.com/stocks/xpar/dg/quote"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 9.9
    },
    {
      "ticker": "FERG",
      "name": "Ferguson Enterprises Inc.",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Industrials",
      "price": 19170.0,
      "currency": "GBP",
      "market_cap": 38471598080,
      "pe_ratio": 26.260273,
      "forward_pe": 23.252579,
      "roe": 33.404,
      "dividend_yield": 138.0,
      "momentum_6m": 16.616244059754326,
      "momentum_12m": 31.685590830856224,
      "rsi_14": 64.28571428571428,
      "alpha_score": 71,
      "score_breakdown": {
        "value": 9,
        "quality": 22,
        "momentum": 25,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/FERG.L",
      "stop_loss": 18310.57,
      "take_profit": 20459.14,
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Ferguson Enterprises is a leading distributor of plumbing, heating, and cooling products serving residential and non-residential markets across North America. The company demonstrated strong operational momentum in Q1 fiscal 2026 (quarter ended October 31, 2025), with revenue growth of 5.1% year-over-year to $8.2 billion and significant margin expansion driving net income up 21.3%[1]. Ferguson maintains a fortress balance sheet with net debt to EBITDA at 1.1x and has returned substantial capital to shareholders while continuing strategic investments[2].",
      "company_overview": "Ferguson Enterprises is a leading distributor of plumbing, heating, and cooling products serving residential and non-residential markets across North America. The company demonstrated strong operational momentum in Q1 fiscal 2026 (quarter ended October 31, 2025), with revenue growth of 5.1% year-over-year to $8.2 billion and significant margin expansion driving net income up 21.3%[1]. Ferguson maintains a fortress balance sheet with net debt to EBITDA at 1.1x and has returned substantial capital to shareholders while continuing strategic investments[2].",
      "key_developments": [
        "**Q1 FY2026 earnings beat on profitability**: Adjusted diluted EPS of $2.84 exceeded consensus estimates of $2.62-$2.77, representing 23.9% growth year-over-year, driven by 80 basis points of operating margin expansion to 9.9%[1][2][3]"
      ],
      "catalysts": [
        "**Non-residential construction cycle continuation**: Sustained double-digit growth in commercial/mechanical and waterworks segments as infrastructure and commercial real estate projects progress through 2026"
      ],
      "risk_factors": [
        "**Valuation compression risk**: At 26.3x P/E, the stock has limited margin of safety; any disappointment in margin expansion or growth deceleration could trigger significant multiple contraction given the 31.7% 12-month return already achieved"
      ],
      "sources": [
        "https://www.quiverquant.com/news/Ferguson+Enterprises+(FERG)+Earnings:+Q1+2026+EPS+Beats+as+Profits+Rise",
        "https://quartr.com/companies/ferguson-enterprises-inc_3672",
        "https://www.investing.com/news/company-news/ferguson-q1-2026-slides-eps-miss-triggers-stock-decline-despite-revenue-beat-93CH-4398910",
        "https://www.youtube.com/watch?v=ZKruzocZHyc",
        "https://www.corporate.ferguson.com/investor/events-results-and-reports/default.aspx",
        "https://www.corporate.ferguson.com/investor/why-ferguson/default.aspx",
        "https://www.marketbeat.com/stocks/NYSE/FERG/earnings/",
        "https://www.corporate.ferguson.com/pressroom/news-releases/news-details/2025/Ferguson-Reports-Quarter-Ended-October-31-2025/default.aspx",
        "https://www.corporate.ferguson.com/investor/financial-information/sec-filings/default.aspx"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 12.7
    },
    {
      "ticker": "ENR",
      "name": "Siemens Energy AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 152.0,
      "currency": "EUR",
      "market_cap": 130012315648,
      "pe_ratio": 95.0,
      "forward_pe": 28.98324,
      "roe": 16.816,
      "dividend_yield": 46.0,
      "momentum_6m": 58.33333333333333,
      "momentum_12m": 166.19965685093595,
      "rsi_14": 71.95574684426185,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 23,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/ENR.DE",
      "stop_loss": 138.99,
      "take_profit": 171.51,
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Siemens Energy's trajectory reflects structural demand in energy transition, grid upgrades, and electrification, bolstered by record orders, margin expansion, and analyst upgrades to \u20ac164-\u20ac170 targets above the current \u20ac152 price.[1][2] Recent US expansions and FY2026 guidance trending toward the upper end signal execution strength, outweighing elevated valuations like a 95x P/E amid 166% 12-month returns.[1][3] Technicals remain supportive with the stock above key moving averages and positive momentum indicators.[1]",
      "company_overview": "Siemens Energy AG is a Germany-based energy technology company focused on power generation, grid technologies, industrial transformation, and renewables including wind turbines via its Siemens Gamesa segment, serving utilities, power producers, and industrial clients globally.[3][1] The company has delivered strong financial performance with double-digit revenue growth, record order intake, and upgraded mid-term targets through fiscal 2028, driving the stock from below \u20ac20 in early 2024 to around \u20ac152 as of early February 2026.[1][2] It operates in a favorable energy-transition context with robust demand for grid infrastructure and electrification solutions.[1]",
      "key_developments": [
        "Deutsche Bank raised its price target to \u20ac170 from \u20ac135 on January 29, 2026, citing improved fundamentals, order pipeline, and profitability outlook amid grid and energy-transition demand.[1]",
        "Jefferies lifted its target to \u20ac164 from \u20ac134 on February 2, 2026, highlighting better earnings visibility and sector tailwinds from grid investments.[1]",
        "Finalized $1 billion US manufacturing expansions, including $421M in North Carolina (announced February 3, 2026) and Alabama production growth, to support energy infrastructure demand.[4][5]",
        "Released strong Q4 FY2025 results in line with upgraded guidance, forecasting 11-13% comparable revenue growth and 9-11% profit margin for FY2026, while raising FY2028 targets to 14-16% margins and low-teens revenue CAGR; also plans \u20ac6bn share repurchases by FY2028 end and an early dividend.[2]"
      ],
      "catalysts": [
        "Full FY2025 earnings release and FY2026 guidance confirmation, potentially affirming upper-end trends and dividend details.[2]",
        "Progress on $1B US expansions and order conversions in grid/energy-transition projects.[4][5]",
        "Further broker updates or sector M&A amid global infrastructure spending.[1]"
      ],
      "risk_factors": [
        "Persistent challenges in the legacy onshore wind business (Siemens Gamesa), including project delays or losses.[1]",
        "High valuation multiples (P/E 95x vs. sector 23.9x) vulnerable to execution misses, macro slowdowns, or sentiment shifts in energy transition.[1][3]",
        "Broader market risks from geopolitical tensions or supply chain issues impacting industrials.[1]"
      ],
      "sources": [
        "https://capital.com/en-int/analysis/siemens-energy-stock-forecast",
        "https://www.siemens-energy.com/global/en/home/investor-relations.html",
        "https://www.investing.com/equities/siemens-energy-ag",
        "https://www.marketscreener.com/news/siemens-energy-finalizes-1-billion-us-expansions-ce7e5bd2d08af626",
        "https://www.perplexity.ai/finance/ENR.DE"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 12.5
    },
    {
      "ticker": "SAF",
      "name": "Safran SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 308.0,
      "currency": "EUR",
      "market_cap": 128284680192,
      "pe_ratio": 29.758453,
      "forward_pe": 29.628347,
      "roe": 34.745997,
      "dividend_yield": 94.0,
      "momentum_6m": 5.987609611503686,
      "momentum_12m": 26.409959646058656,
      "rsi_14": 39.782594994443805,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 20,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/SAF.PA",
      "stop_loss": 293.7,
      "take_profit": 329.45,
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Safran's strong fundamentals (high ROE of 27.93-34.7%, \u20ac3.8 EPS, superior interest coverage of 51.92 vs. peers) and trading at a 546% premium to Morningstar's \u20ac391 fair value support upside potential in a recovering aviation market.[1][2] Recent all-time highs and 45%+ yearly returns indicate sustained momentum, though elevated P/E (29.8-38.74) warrants caution on valuations.[1][2]",
      "company_overview": "Safran SA is a leading French aerospace and defense company specializing in aircraft engines, propulsion systems, and equipment, holding a strong market position as a key supplier to Airbus and Boeing with peers like RTX and GE. It reports robust financials including \u20ac7.85B in sales revenues, \u20ac5.05B net income, 27.93% ROE (normalized), and a market cap of ~\u20ac126B, with shares recently trading around \u20ac305-308 amid a 45.52% 12-month gain.[1][2][4] The stock hit all-time highs multiple times in late 2025 (e.g., \u20ac305.80 on 2025-10-03) and remains near peaks despite a Q4 forecast of \u20ac296.34.[1]",
      "key_developments": [
        "Shares traded at \u20ac305.30 on October 28, 2025, up 0.56% daily and 3.21% over prior 4 weeks, with 45.52% yearly gains; recent data shows volatility around \u20ac300 in early February 2026 (e.g., \u20ac302.50 on Feb 05).[1][3]",
        "Stock reached \u20ac308 on February 6, 2026, up 1.82%, reflecting continued upward momentum from 2025 highs.[4]",
        "No major company-specific news in the last 30 days (early January to February 8, 2026); price action driven by broader aerospace sector strength and macro forecasts.[1][3]"
      ],
      "catalysts": [
        "Q4 2026 earnings and guidance, potentially confirming sales growth and backlog execution amid rising air travel demand.[1]",
        "Aerospace sector recovery catalysts like Airbus/Boeing production ramps, benefiting Safran's engine supply chain.[2]"
      ],
      "risk_factors": [
        "Downward price forecasts (Q4 at \u20ac296.34, 1-year at \u20ac273.15), signaling potential near-term pullback from current \u20ac305-308 levels.[1]",
        "High valuation multiples (P/E 38.74, trading far above fair value per some models) vulnerable to economic slowdowns or aviation demand weakness.[2]"
      ],
      "sources": [
        "https://tradingeconomics.com/saf:fp",
        "https://www.morningstar.com/stocks/xpar/saf/quote",
        "https://www.investing.com/equities/safran-historical-data",
        "https://www.safran-group.com/finance/safran-share-price",
        "https://www.safran-group.com/finance/glance",
        "https://finbox.com/ENXTPA:SAF/"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 12.5
    },
    {
      "ticker": "GSK",
      "name": "GSK plc",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 2198.0,
      "currency": "GBP",
      "market_cap": 88211988480,
      "pe_ratio": 15.812949,
      "forward_pe": 11.246936,
      "roe": 43.310001,
      "dividend_yield": 328.0,
      "momentum_6m": 56.58391015225654,
      "momentum_12m": 50.0471949090997,
      "rsi_14": 85.63432835820896,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 19,
        "momentum": 23,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/GSK.L",
      "stop_loss": 2086.98,
      "take_profit": 2364.52,
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "GSK plc is a British pharmaceutical giant with a diversified portfolio spanning specialty medicines, vaccines, and general medicines. The company delivered strong 2025 performance with turnover rising 4% to \u00a332.6 billion and core operating profit up 11%, driven primarily by double-digit growth in its Specialty Medicines division (Respiratory, Immunology & Inflammation, Oncology, and HIV)[1][3]. Under new CEO Luke Miels (appointed January 2026), GSK is executing a strategic pivot toward higher-margin specialty products while managing patent expirations in its general medicines portfolio.",
      "company_overview": "GSK plc is a British pharmaceutical giant with a diversified portfolio spanning specialty medicines, vaccines, and general medicines. The company delivered strong 2025 performance with turnover rising 4% to \u00a332.6 billion and core operating profit up 11%, driven primarily by double-digit growth in its Specialty Medicines division (Respiratory, Immunology & Inflammation, Oncology, and HIV)[1][3]. Under new CEO Luke Miels (appointed January 2026), GSK is executing a strategic pivot toward higher-margin specialty products while managing patent expirations in its general medicines portfolio.",
      "key_developments": [
        "**Q4 2025 Results Beat Expectations**: GSK reported Q4 core EPS of 68 cents (beating consensus of 64 cents) and revenue of $11.46 billion (\u00a38.62 billion), with specialty medicines sales rising 18% driven by strong demand for HIV, oncology, and respiratory treatments[2]."
      ],
      "catalysts": [
        "**2026 Commercial Execution**: Management's emphasis on \"commercial launches\" suggests multiple specialty medicine launches planned for 2026, which could drive upside to guidance if successful[1]."
      ],
      "risk_factors": [
        "**Patent Cliff Exposure**: GSK faces material patent expirations beginning in 2028 for HIV treatments, a key growth driver, which could pressure revenues if new products fail to compensate[5]."
      ],
      "sources": [
        "https://www.nasdaq.com/articles/gsk-q4-results-climb-sees-growth-fy26-backs-2031-sales-view-update",
        "https://www.zacks.com/stock/news/2828654/gsks-q4-earnings-sales-beat-estimates-stock-up-on-26-outlook",
        "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/",
        "https://www.gurufocus.com/news/8580044/gsk-projects-moderate-growth-in-turnover-and-earnings-by-2026?mobile=true",
        "https://www.voxmarkets.com/articles/gsk-sees-slower-sales-growth-in-2026-as-patent-loss-looms-7c4f7f2",
        "https://www.ig.com/uk/news-and-trade-ideas/gsk-full-year-earnings--can-the-pharma-giant-deliver-on-post-dem-260203",
        "https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 12.5
    },
    {
      "ticker": "RIO",
      "name": "Rio Tinto Group",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Basic Materials",
      "price": 6843.0,
      "currency": "GBP",
      "market_cap": 111193030656,
      "pe_ratio": 14.716128,
      "forward_pe": 12.19558,
      "roe": 17.158002,
      "dividend_yield": 416.0,
      "momentum_6m": 49.673994048695945,
      "momentum_12m": 36.53139134072427,
      "rsi_14": 66.68874172185431,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 22,
        "momentum": 25,
        "catalyst": 0,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/RIO.L",
      "stop_loss": 6429.29,
      "take_profit": 7463.57,
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Rio Tinto's pivot to high-growth copper and lithium, combined with project execution like Oyu Tolgoi and Simandou, positions it for earnings expansion despite iron ore headwinds, supported by undervaluation metrics and H1 2025 resilience.[1][2] Strong cash conversion (60%) and disciplined capex ($4.7 billion H1) fund long-term value, with diversification mitigating commodity volatility.[1] Recent momentum and peer-lagging returns suggest market underappreciation of forward catalysts.[2]",
      "company_overview": "Rio Tinto Group is a global mining leader focused on iron ore, aluminium, copper, and emerging areas like lithium, with strong diversification efforts amid iron ore price pressures. For H1 2025, it reported resilient Underlying EBITDA of $11.5 billion (down 5% YoY) and operating cash flow of $6.9 billion (down 2% YoY), offset by robust growth in aluminium (50% EBITDA uplift) and copper (69% uplift), despite a 13% iron ore price decline.[1] The balance sheet remains solid with high-grade credit ratings, though net debt rose to $14.6 billion post-Arcadium Lithium acquisition, supporting a 50% interim dividend payout.[1]",
      "key_developments": [
        "Accelerated Simandou iron ore project in Guinea, targeting first shipment by November 2025, enhancing future iron ore output.[1]",
        "Oyu Tolgoi copper mine in Mongolia ramped up 54% YoY in H1 2025 production, on track for ~500 ktpa average from 2028-2036, with lower C1 unit costs.[1]",
        "Share price at \u00a366.76 showed strong momentum: +5.3% (7 days), +11.6% (30 days), +44.7% (1 year), trading undervalued per DCF (19.1% discount) and P/E (14.47x vs. fair ratio 29.03x).[2]"
      ],
      "catalysts": [
        "First Simandou iron ore shipment (November 2025), boosting production and revenue predictability.[1]",
        "Oyu Tolgoi ramp-up milestones toward 500 ktpa copper (2028+), plus 2025 annual results on 19 February 2026.[1][5]",
        "2026 final dividend ex-date, maintaining 50% payout policy amid improving copper/aluminium contributions.[1][4]"
      ],
      "risk_factors": [
        "Iron ore price volatility and external disruptions like cyclones, which pressured H1 2025 EBITDA.[1]",
        "Elevated capex ($10-11 billion mid-term) and rising net debt from acquisitions, potentially squeezing FCF if projects delay.[1]"
      ],
      "sources": [
        "https://www.tikr.com/blog/can-rio-tintos-aggressive-pivot-to-lithium-and-copper-projects-sustain-growth-in-2026",
        "https://simplywall.st/stocks/gb/materials/lse-rio/rio-tinto-group-shares/news/has-the-market-fully-reflected-rio-tinto-lserios-strong-rece",
        "https://www.riotinto.com/en/invest/reports",
        "https://www.riotinto.com/en/invest/financial-calendar",
        "https://www.riotinto.com/en/invest/financial-news-performance"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 12.5
    },
    {
      "ticker": "AMAT",
      "name": "Applied Materials, Inc.",
      "exchange": "US",
      "index": "NASDAQ_SELECT",
      "sector": "Technology",
      "price": 322.51,
      "currency": "USD",
      "market_cap": 255983124480,
      "pe_ratio": 37.15553,
      "forward_pe": 26.492924,
      "roe": 35.508,
      "dividend_yield": 56.99999999999999,
      "momentum_6m": 75.29524861161806,
      "momentum_12m": null,
      "rsi_14": 48.28819156800613,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 17,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AMAT",
      "stop_loss": 290.09,
      "take_profit": 371.14,
      "signal": "HOLD",
      "confidence": "MEDIUM",
      "reasoning": "Applied Materials is a **semiconductor equipment manufacturer** serving the global chip production industry, with particular exposure to advanced chip fabrication for AI, data centers, and electric vehicles[2]. The company has experienced exceptional momentum, with an 80.97% one-year total shareholder return and a 37.19% three-month return, driven by robust demand for chipmaking equipment tied to AI infrastructure buildout[2]. However, the stock is trading at a premium valuation with a P/E ratio of 37.16 and is currently considered overvalued by fundamental analysis[2].",
      "company_overview": "Applied Materials is a **semiconductor equipment manufacturer** serving the global chip production industry, with particular exposure to advanced chip fabrication for AI, data centers, and electric vehicles[2]. The company has experienced exceptional momentum, with an 80.97% one-year total shareholder return and a 37.19% three-month return, driven by robust demand for chipmaking equipment tied to AI infrastructure buildout[2]. However, the stock is trading at a premium valuation with a P/E ratio of 37.16 and is currently considered overvalued by fundamental analysis[2].",
      "key_developments": [
        "**Strong recent earnings beat**: Applied Materials reported Q4 FY2025 EPS of $2.17 (beating consensus of $2.11) and revenue of $6.80B (exceeding estimate of $6.68B), though revenue declined 3.5% year-over-year[1]",
        "**Aggressive analyst upgrades**: Deutsche Bank upgraded the stock from \"hold\" to \"buy\" with a $390 price target (January 23), KeyCorp raised its target to $380 (January 16), and Morgan Stanley increased its target to $364, reflecting confidence in AI chip equipment demand[1]",
        "**Consensus analyst view**: 24 buy ratings and 8 hold ratings with an average price target of $315.15, representing modest downside from current levels[1]",
        "**Upcoming earnings catalyst**: Q1 FY2026 earnings report scheduled for February 12, 2026, with consensus expectations for EPS of $2.19 (down 7.98% year-over-year) and revenue of $6.86B (down 4.34% year-over-year)[5]"
      ],
      "catalysts": [
        "**Q1 FY2026 earnings report (February 12, 2026)**: Management guidance on AI chip equipment demand sustainability and capital spending trends will be pivotal for near-term stock direction[3]",
        "**Potential upside to $320-$325 resistance**: Technical analysis suggests a $320.93 target with modest 5.6% upside, though this represents a key resistance level where the stock may consolidate[4]",
        "**Full-year FY2026 guidance**: Consensus expects full-year EPS of $9.54 (+1.27% YoY) and revenue of $29.03B (+2.34% YoY), indicating modest growth expectations despite AI tailwinds[5]"
      ],
      "risk_factors": [
        "**Valuation risk**: The stock trades at a PEG ratio of 2.94 versus an industry average of 2.02, and fundamental analysis suggests 40%+ downside to fair value if growth assumptions disappoint[2][5]",
        "**China export controls**: Sustained restrictions on semiconductor equipment exports to China could significantly constrain revenue growth and challenge the bullish narrative[2]",
        "**Cyclical semiconductor spending pullback**: A sharp reversal in capital spending by chipmakers following the current AI infrastructure boom could rapidly deflate equipment demand and multiples[2]",
        "**Year-over-year earnings decline**: Q1 FY2026 is expected to show declining earnings and revenue compared to the prior year, suggesting the growth cycle may be moderating[5]",
        "**Momentum-driven valuation**: The 75%+ six-month return reflects momentum rather than fundamental improvement, creating vulnerability to profit-taking or sentiment shifts[2]"
      ],
      "sources": [
        "https://www.marketbeat.com/instant-alerts/applied-materials-nasdaqamat-trading-up-61-whats-next-2026-02-06/",
        "https://simplywall.st/stocks/us/semiconductors/nasdaq-amat/applied-materials/news/a-look-at-applied-materials-amat-valuation-after-bullish-bro",
        "https://www.nasdaq.com/articles/applied-materials-amat-expected-beat-earnings-estimates-can-stock-move-higher",
        "https://www.tikr.com/blog/applied-materials-surged-6-on-equipment-boom-path-to-a-320-breakout-in-2026",
        "https://www.zacks.com/stock/news/2828386/heres-why-applied-materials-amat-fell-more-than-broader-market",
        "https://www.tipranks.com/news/applied-materials-stock-amat-plunges-despite-hopes-for-a-more-constructive-direction",
        "https://www.gurufocus.com/news/8596486/science-technology-fund-sells-520-shares-of-applied-materials-inc-amat"
      ],
      "target_timeframe": "3-6 months",
      "suggested_pct": 4.8
    }
  ],
  "dashboard_stats": {
    "has_history": true,
    "total_predictions": 40,
    "timeframes": [
      "30d",
      "60d",
      "90d"
    ],
    "default_timeframe": "90d",
    "timeframe_stats": {
      "30d": {
        "evaluated": 0,
        "pending": 40,
        "correct": 0,
        "incorrect": 0,
        "inconclusive": 0,
        "win_rate": null,
        "per_signal": {
          "BUY": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "HOLD": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "AVOID": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          }
        }
      },
      "60d": {
        "evaluated": 0,
        "pending": 40,
        "correct": 0,
        "incorrect": 0,
        "inconclusive": 0,
        "win_rate": null,
        "per_signal": {
          "BUY": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "HOLD": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "AVOID": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          }
        }
      },
      "90d": {
        "evaluated": 0,
        "pending": 40,
        "correct": 0,
        "incorrect": 0,
        "inconclusive": 0,
        "win_rate": null,
        "per_signal": {
          "BUY": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "HOLD": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          },
          "AVOID": {
            "total": 0,
            "correct": 0,
            "decisive": 0,
            "accuracy": null,
            "avg_return": null
          }
        }
      }
    },
    "evaluated": 0,
    "pending": 40,
    "correct": 0,
    "incorrect": 0,
    "inconclusive": 0,
    "win_rate": null,
    "per_signal": {
      "BUY": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "HOLD": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "AVOID": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      }
    },
    "streaks": {
      "DG": 1,
      "GSK": 2,
      "RIO": 2,
      "AMAT": 2,
      "AZN": 2,
      "ENR": 2,
      "SAF": 2,
      "FERG": 2,
      "TKA": 2,
      "EN": 2
    },
    "weight_overrides": {},
    "active_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "base_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "recent_evaluations": [],
    "performance_timeline": [
      {
        "date": "2026-02-07",
        "win_rate": null,
        "total_predictions": 20,
        "evaluated": 0,
        "correct": 0,
        "avg_return": null,
        "buy_accuracy": null,
        "hold_accuracy": null,
        "avoid_accuracy": null
      },
      {
        "date": "2026-02-08",
        "win_rate": null,
        "total_predictions": 40,
        "evaluated": 0,
        "correct": 0,
        "avg_return": null,
        "buy_accuracy": null,
        "hold_accuracy": null,
        "avoid_accuracy": null
      }
    ]
  }
}